Education
About Us
Working with TipRanks
Follow Us
BioCardia Inc (BCDA)
NASDAQ:BCDA
BCDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.63 - $6.15
Previous CloseN/A
Volume12.78K
Average Volume (3M)81.69K
Market Cap
$9.41M
Enterprise Value$8.61M
Total Cash (Recent Filing)$2.37M
Total Debt (Recent Filing)$951.00K
Price to Earnings (P/E)―
Beta2.16
Next Earnings
May 07, 2025EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.34
Shares Outstanding4,680,005
10 Day Avg. Volume165,661
30 Day Avg. Volume81,695
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)171.75
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit148.45
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$6.00Price Target Upside198.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
BioCardia News
PremiumCompany Announcements
BioCardia’s Earnings Call Highlights Strong Trial ResultsPremiumCompany Announcements
BioCardia Clarifies Timing for CardiAMP-HF Results Call
PremiumCompany Announcements
BioCardia Reports Positive Phase 3 CardiAMP-HF Results
PremiumPre-Earnings
Is BCDA a Buy, Before Earnings?
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBiocardia announced financial results with an EPS better than the analyst's estimate, indicating better-than-expected financial performance.
Financial StabilityThe company has enough cash to fund ongoing operations through the first quarter of 2025, providing financial stability in the near term.
Product LaunchMorph DNA Introducer now commercially available, providing new revenue stream.
Bears Say
Clinical Trial OutcomeDSMB determined that the study would not meet the primary Finkelstein Schoenfeld composite endpoint and recommended to pause enrollment.
---
Ownership Overview
21.87% Insiders
0.61% Mutual Funds
0.57% Other Institutional Investors
76.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BCDA FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was $1.63 and its highest was $6.15 in the past 12 months.
What is BioCardia Inc’s market cap?
BioCardia Inc’s market cap is $9.41M.
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is May 07, 2025 which is in 30 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on Mar 26, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.625 by $0.565.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate is -0.63.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 4,680,005 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.625. Following the earnings report the stock price went up 5.098%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in BCDA
---
Company Description
BioCardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
---
BCDA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong set of trial results with significant reductions in heart failure risks and improvements in quality of life. Financial management showed positive trends with reduced expenses and losses. Despite not meeting the primary endpoint, the data was compelling enough to support ongoing regulatory discussions and future trials. However, the unexpected negative market reaction was a noted concern.Read More>---
BCDA Stock 12 Month Forecast
Average Price Target
$6.00
▲(198.51% Upside)
Technical Analysis
Leap Therapeutics
―
Citius Pharmaceuticals
―
BioRestorative Therapies
―
Sensei Biotherapeutics
―
HCW Biologics
―
Best Analysts Covering BCDA
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-34.42%
reiterated a buy rating 4 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -34.42% per trade.
---